---
title: "VK2735 in Chronic weight management: Administration"
description: "Formulary evidence on VK2735 in Chronic weight management: Administration. Topics: Subcutaneous formulation: once-weekly subcutaneous injection in the phase 3 trials; Subcutaneous formulation: dosing without regard to fasting in the phase 2 trial; Subcutaneous formulation: vial and syringe, then an autoinjector after a bioequivalence study; Subcutaneous formulation: autoinjector use and clinic visit frequency in the phase 3 trials; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/administration"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Instructions for use, injection sites, and storage

No evidence found.

<a id="topic-2.1.2.10.2-2"></a>

### Subcutaneous formulation: once-weekly subcutaneous injection in the phase 3 trials

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-2.1.2.10.2-3"></a>

### Subcutaneous formulation: dosing without regard to fasting in the phase 2 trial

> “On study days with PK sample collection scheduled, participants were similarly asked to fast for no less than 6 h. Fasting was not otherwise required for dosing.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.10.2-4"></a>

### Subcutaneous formulation: vial and syringe, then an autoinjector after a bioequivalence study

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735. In the fourth quarter of 2025, we initiated a bioequivalence study to allow for the introduction of an autoinjector device, which may represent a more convenient method of administration for some people. We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="topic-2.1.2.10.2-5"></a>

### Subcutaneous formulation: autoinjector use and clinic visit frequency in the phase 3 trials

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector. I think for VANQUISH 2, almost everybody is on the auto-injector.”
> “Your clinic visits drop from four per month to one per month.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-2.1.2.10.2-6"></a>

### Subcutaneous formulation: vial and syringe in the maintenance study

> “These are going to be a vial and syringe. The study's well underway now, so no, we're not going to introduce the autoinjector in the maintenance study.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

<a id="topic-2.1.2.10.2-7"></a>

### Oral formulation: once-daily tablet in the phase 3 trials

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.2-8"></a>

### Oral formulation: administration relative to food, water, and other oral medications

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
